BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pfeiffer R. Beyond here be dragons: SIBO in Parkinson’s disease. Mov Disord. 2013;28:1764-1765. [PMID: 24167009 DOI: 10.1002/mds.25705] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun 2019;10:310. [PMID: 30659181 DOI: 10.1038/s41467-019-08294-y] [Cited by in Crossref: 127] [Cited by in F6Publishing: 116] [Article Influence: 42.3] [Reference Citation Analysis]
2 Johnson ME, Stringer A, Bobrovskaya L. Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson’s disease. NeuroToxicology 2018;65:174-85. [DOI: 10.1016/j.neuro.2018.02.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
3 Arneth BM. Gut–brain axis biochemical signalling from the gastrointestinal tract to the central nervous system: gut dysbiosis and altered brain function. Postgrad Med J 2018;94:446-52. [DOI: 10.1136/postgradmedj-2017-135424] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
4 Del Chierico F, Grassini P, Quagliariello A, Torti M, Russo A, Reddel S, Stocchi F. The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study. Future Microbiol 2020;15:1393-404. [PMID: 33085540 DOI: 10.2217/fmb-2019-0336] [Reference Citation Analysis]
5 Çamcı G, Oğuz S. Association between Parkinson's Disease and Helicobacter Pylori. J Clin Neurol 2016;12:147-50. [PMID: 26932258 DOI: 10.3988/jcn.2016.12.2.147] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
6 Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 2015; 21(37): 10609-10620 [PMID: 26457021 DOI: 10.3748/wjg.v21.i37.10609] [Cited by in CrossRef: 312] [Cited by in F6Publishing: 276] [Article Influence: 44.6] [Reference Citation Analysis]
7 Bindas AJ, Kulkarni S, Koppes RA, Koppes AN. Parkinson's disease and the gut: Models of an emerging relationship. Acta Biomater 2021;132:325-44. [PMID: 33857691 DOI: 10.1016/j.actbio.2021.03.071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow SK, Tan CT. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:535-540. [PMID: 24637123 DOI: 10.1016/j.parkreldis.2014.02.019] [Cited by in Crossref: 136] [Cited by in F6Publishing: 123] [Article Influence: 17.0] [Reference Citation Analysis]
9 Ibrahim A, Ali RAR, Manaf MRA, Ahmad N, Tajurruddin FW, Qin WZ, Desa SHM, Ibrahim NM. Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial. PLoS One 2020;15:e0244680. [PMID: 33382780 DOI: 10.1371/journal.pone.0244680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Vascellari S, Palmas V, Melis M, Pisanu S, Cusano R, Uva P, Perra D, Madau V, Sarchioto M, Oppo V, Simola N, Morelli M, Santoru ML, Atzori L, Melis M, Cossu G, Manzin A. Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease. mSystems 2020;5:e00561-20. [PMID: 32934117 DOI: 10.1128/mSystems.00561-20] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
11 Lei Q, Wu T, Wu J, Hu X, Guan Y, Wang Y, Yan J, Shi G. Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review). Mol Med Rep 2021;24:734. [PMID: 34414447 DOI: 10.3892/mmr.2021.12374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wollmer E, Klein S. A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson’s disease. International Journal of Pharmaceutics 2017;533:298-314. [DOI: 10.1016/j.ijpharm.2017.08.126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]